&#xa0;
default&#xa0;default&#xa0;defaultIntroduction
default&#xa0;default1.
default&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; 
defaultResearch Councils UK (RCUK) is a strategic partnership set up to champion the research supported by the seven UK Research Councils. RCUK was established to enable the Councils to work together more effectively to enhance the overall impact and effectiveness of their research, training and innovation activities, and contributing to the delivery of the Government’s objectives for science and innovation.
default 
default&#xa0;default2.
default&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; 
defaultThis response is submitted by RCUK 
defaulton behalf of the following research c
defaultouncils:
default&#xa0;default&#xa0;
default3.
default&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; 
defaultAntimicrobial resistance has been of growing concern to RCUK for the past few years and we are encouraged that the profile has been raised at the highest levels.  
defaultWe welcome the opportunity to provide evidence to the Committee and have focuse
defaultd on those questions that fall within our combined remit and expertise.
default&#xa0;
defaultSummary
default&#xa0;
default4.
default&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; 
defaultThe
default challenges raised by antimicrobial resistance require a broad approach
default. This approach should
default encompass new therapeutic agents
default, alternative strategies for controlling disease
default, diagnostics, surveillance, modelling, transmission dynamics
default as well as health systems
default, behaviour change
default and implementation -all
default built on strong underpinning biology of the organisms and the hosts.
default&#xa0;
default5.
default&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; 
defaultThe research councils
default’
default 
defaultbroad 
defaultremit
defaults
default 
defaultallow support 
defaultto 
defaultaddress antimicrobial resistance across the whole of the research 
defaultspectrum
default. However, the level of activity needed to address this issue can only be achieved through collaborative working, bringing together disciplines in a coordinated way.  This will require a coordinated response between the research councils
default, government departments, 
defaultother research funders in the UK
default and industry
default.
default&#xa0;
defaultResponse
default&#xa0;
defaultWhat are the gaps in our knowledge about antimicrobial resistance? 
default&#xa0;
default6.
default&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; 
defaultAntimicrobial resistance has been of growing concern to RCUK for the past few years and the research councils have identified a number of gaps and areas of research need. Activities that have helped inform priorities include an MRC 
defaultmeeting
default in July 2013 
defaultto identify 
defaultresearch 
defaultneeds in this area
default and joint research council work
default with the Wellcome Trust to investigate why there has been a lack of development in the pharma pipeline
default,
default and with EU partners to identify gaps and opportunities. 
defaultAlso, in February 2013 STFC and the Royal United Services Institute (RUSI) organised a workshop looking at gaps in research knowledge resulting in an RUSI 
defaultOccasional Paper, “Tackling Antimicrobial Resistance: Identifying Future Research Themes”
default. 
default&#xa0;
default7.
default&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; 
defaultThe ESRC is monitoring closely the current NIHR themed call in antimicrobial resistance with a view to determining any future research needs in the social and behavioural sciences.
default&#xa0;
default8.
default&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; 
defaultIt is clear that across the UK there is expertise in a range of 
defaultdisciplines that could be brought to bear on the 
defaultfollowing 
defaultissues:
default&#xa0;
default&#xa0;
defaultThis is not an exhaustive list - there are a range of research areas across the councils that could impact antimicrobial resistance.
default&#xa0;
default9.
default&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; 
defaultAntibacterial resistance 
defaultis also an important issue for a
defaultnimal
default health – from 
defaultan animal health, welfare and production perspective 
defaultand 
defaultalso 
defaultconcerns 
defaultaround 
defaultthe potential risk to humans of antibiotic resistance in zoonotic organisms (although the EU has banned all non-therapeutic use of antibiotics). 
defaultThere is a gap in our understanding of the extent to which 
defaultantimicrobial resistance
default arises from animal sources versus hum
defaultans, and the extent to which antimicrobial resistance
default (specifically antibiotic resistance) has been transferred from animals (see, for example, recent studies on the origins of MRSA
default). Further work on how changes in farm business models impact use of antibiotics would also be helpful.
default&#xa0;
default10.
default&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; 
defaultIn addition to antibacterial resistance, 
defaultthe issue of anthelminthic resistance is a major problem for the farming industry.  Anthelminthics are used to treat helminth parasites and protozoa infestation in ruminants, pigs and poultry and unlike antibiotics there are only 
defaultthree 
defaultmajor families of an
defaultthelmintic drugs
default. 
defaultW
defaultidespread resistance
default to these drugs has been
default reported in most UK sheep farms.
default&#xa0;
default11.
default&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; 
defaultAdvances in 
defaultdisease surveillance and 
defaultpoint-of-care diagnostics, and particularly the application of rapid whole genome sequencing, are likely to change the antimicrobial market over the next 10-15 years. Molecular diagnostic tools can also be used to track the spread of resistant organisms and identify if an organism has become resistant to a particular treatment.  
default&#xa0;
default12.
default&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; 
defaultCurrently
default, however, development of reliable, high throughput and rapid diagnostic systems, ideally capable of operating successfully in a clinical rather than laboratory environment remains
default 
defaulta significant gap
default. 
defaultR
defaultesearch challenges 
defaulthere 
defaultinclude
default 
defaultdata mining for biomarker d
defaultiscovery,
default 
defaultadvanced
default 
defaultnanomaterials, microfluidics, sensor systems,
default 
defaultmicroelectronics
default 
defaultand
default 
defaulttelecommunications. For disease surveillance there are big data research challenges
default to be addressed such as
default 
defaultinnov
defaultative web-tracking technologies and
default mathematical modelling of epidemics.  
default&#xa0;
default13.
default&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; 
defaultT
defaulthe 
defaultresearch councils
default, often in partnership with the Technology Strategy 
defaultBoard (
defaultTSB)
default,
default 
defaultare
default invest
defaulting
default in a number
default of projects to develop and test novel diagnostic
defaults
default.  For example, EPSRC has recently established an 
default£11
default 
defaultm
defaultillion
default 
defaultinterdisciplinary research centre in University College London to create a new generation of early-warning sensing systems for diagnosis, monitoring 
defaultand 
defaultprevention of the spread of infectious diseases.  
defaultThe 
defaultMRC has worked in partnership with TSB to fund 
defaultresearch on 
defaultthe
default detection and 
defaultidentification 
defaultof 
defaultinfectious agents
default.  
defaultDespite this investment
default, 
defaultdiagnostics
default remains priority area for the field.
default&#xa0;
default14.
default&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; 
defaultThe MRC, on behalf of 
defaultthe 
defaultUK 
defaultresearch councils and 
defaultbiomedical research 
defaultfunders, has been working with colleagues
default from EU member and accession states
default on a Joint Programming Initiative 
defaulton 
defaultAntimicrobial Resistance
default.  As part of this
default activity
default, a strategic research agenda 
defaultis being developed
default and is due to be 
defaultlaunched in March 2014.  This will highlight a range of gaps and opportunities to be addressed through international cooperation.  
defaultThe research agenda will be broad encompassing scientific, societal and environmental challenges.
default&#xa0;
defaultIs there sufficient research and investment into new antibiotics or other treatments and methods to ensure continued protection against infection? If not, how could this be rectified? 
default&#xa0;
default15.
default&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; 
defaultIn May 2013 
defaultBBSRC, MRC and the Wellcome Trust 
defaultsupported 
defaulta one day symposium ‘Lessons to be learnt from Pharma about drug discovery and development of new antibacterial drugs’
default,
default organised by Antibiotic Action.  The 
defaultreport
default 
defaultnoted that: 
default&#xa0;
default‘New antibiotic development has slowed alarmingly in recent decades, and the antibiotic development pipeline is poorly stocked. This lack of activity reflects ‘market failure’ – pharmaceutical companies have retreated from antibiotic development as the risk–reward ratio has been considered unattractive’.  
default&#xa0;
default16.
default&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; 
defaultThe supply pipeline of new therapeutic agents is seen by many as a commercial 
defaultissue 
defaultbut d
defaultirected R&amp;D 
defaultin partnership with
default the research councils 
defaultcould increase the efficiency of the se
defaultarch for new therapeutic agents, 
defaultidentif
defaultication of
default new ones
default and improved the development processes for getting to market
default.
default&#xa0;
default17.
default&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; 
defaultHowever, the major impediment to drug discovery is the 
defaultcurrent
default economic model which makes private sector investment by large pharmaceutical companies less attractive in this area than many others (e.g
default.
default chemotherapy and treatments for long term degenerative disorders)
default.
default There are discussions around 
defaultchanging the 
defaultbusiness models to make discovery more attractive for industry partners
default and
default research into new business models
default could be taken forward 
defaultby the ESRC 
defaultand/
defaultor TSB.
default&#xa0;
default18.
default&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; 
defaultThe level of investment from the pharma
defaultceutical
default industry will need to be addressed by that sector.  However, 
defaultBBSRC, EPSRC and the MRC
default all
default invest significantly in 
defaultresearch on basic 
defaultmicrobiology
default and 
defaulton 
defaultantimicrobial 
defaultresistance
default.  
defaultIn 2011/2012 the MRC, BBSRC and EPSRC invested approximately £
default19.6
defaultm
default in antimicrobial resistance research
default. This excludes 
defaultmajor
default investments into the underpinning basic biology of the organisms or the hosts. 
defaultHowever, EPSRC’s investment includes developing epidemiological models of infectious diseases, techniques to diagnose and monitor infectious diseases and novel antimicrobial therapeutics/agents in response to drug resistance.  
default 
default&#xa0;
default19.
default&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; 
defaultIn terms of investment directly into developing new antibiotics or treatments, 
defaultthere has been major investment by the European Commission and European Federation of Pharmaceutical Industries and Associations (EFPIA) through the Innovative Medicines Initiative
default (IMI)
default. To date, 
defaultthe Commission and EFPIA
default have jointly committed €
default431m 
defaultto 
defaultfive 
defaultAMR consortia - 
defaultapproximately a quarter of all IMI research commitment.
default  The MRC is the BIS appointed UK representative on the State Representative Group for the IMI.
default&#xa0;
default20.
default&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; 
defaultThere is 
defaulta broad 
defaultrecognition that the purely genomic approach used by some pharma
defaultceutical companies
default to identify new targets over the past 10 years has not yielded results.  
defaultThe research councils consider that a
default more holistic approach is needed to better understand cellular mechanisms, identify putative targets through genomics but couple this with whole-cell based assays and better animal models. 
default&#xa0;
default21.
default&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; 
defaultT
defaulthe
default researc
defaulth councils recognise that there
default is much 
defaultthey
default 
defaultcan do to 
defaultsupport 
defaultdrug discovery and development
default at earlier stages
default.  
default 
defaultI
defaultmproved target identification and validation 
defaultis needed 
defaultwith
default 
defaultbetter
default screening to ensure that putative targets are “druggable” and 
defaultthat 
defaultattacking the target will effectively kill the organism.  This should also include 
defaultscreening for resistance at the earliest stages.  Research should continue on proven targets as 
defaultwell as 
defaultidentifying new 
defaulttargets
default.  
default&#xa0;
default22.
default&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; 
defaultNew
default approaches might include the application of novel chemistry to discover new targets, to manipulate current drugs to prevent resistance, and to potentially rescue old compounds which have not reached the clinic due to toxicity or lack of efficacy.  In addition to novel chemistry, synthetic biology can create novel advantageous analogues of known antibiotics and apply structure-informed de novo drug-design to overcome resistance mechanisms, toxicity issues and, importantly to ensure that drugs are able to enter the organisms.  
default&#xa0;
default23.
default&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; 
defaultThere also remains a large untapped resource of microbial, plant and animal sources and underexplored environmental niches 
defaultthat may 
defaultyield novel molecules and scaffolds on which to base new antibiotics.  Exploration of these sources in a thorough and 
defaultco-ordinated way may offer new treatments for infectious diseases.
default&#xa0;
default24.
default&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; 
defaultO
defaultpportunities exist for disease control strategies that avoid the use of antimicrobial drugs/agents 
defaultsuch as the developing novel vaccines, 
defaultincluding ve
defaultterinary vaccines, against bacterial infection or immunotherapies for the bacteria or the toxins they produce.
default 
default&#xa0;
default25.
default&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; 
defaultMore broadly 
defaultthe control and transmission of infection is effected via 
defaultpeople, 
defaultsurfaces, interfaces and materials (including those within medical devices
default, dressings etc.
default) 
defaultthat 
defaultcome into contact with 
defaultother 
defaulthumans, animals and the environment. Opportunities exist for frontier 
defaultr
defaultesearch at the interface between advanced materials, engineering sciences, modelling, pharmaceutical sciences, life 
defaultsciences
default, 
defaultbehavioural and 
defaultclinical 
defaultscience
default.
default&#xa0;
default26.
default&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; 
defaultIt is the research council
defaults’
default view that development and front-line deployment of a viable and cost effective means of addressing the challenge requires a broad focus encompassing new therapeutic agents
default, alternative strategies for controlling disease
default, diagnostics, surveillance, modelling, transmission dynamics
default, health care systems and behaviour change all
default built on strong underpinning biology of the organisms and the hosts.
default&#xa0;
default27.
default&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; 
defaultT
defaulthis 
defaultlevel of 
defaultactivity 
defaultcan only
default be achieved through collaborative working, bringing together disciplines 
defaultand sectors 
defaultin a coordinated 
defaultway.  This will require a coordinated response between the 
defaultresearch councils 
defaultand other funders in the UK as well as industry.
default&#xa0;
default28.
default&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; 
defaultResearch will also need to cross human/animal boundaries. 
defaultMultidisciplinary collaborations between researchers working on AMR in organisms present in humans, animals and the environment under a ‘
defaultone health’ approach is important to the strategy for investment in AMR research. 
default 
default&#xa0;defaultWhat global coordination and action is required to fight antimicrobial resistance and is the UK contributing enough towards cross-border initiatives?
default&#xa0;
default29.
default&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; 
defaultGlobal coordination will be requ
defaultired for a number of activities.  For example, detection and monitoring, both nationally and internationally, of the emergence and spread of both new diseases and new antibiotic strains of existing disease-causing organisms.
default 
defaultThis could also cover 
defaultsurveillance of 
defaultresistance strains and transmission dynamics
default of resistance
default.  The UK has been actively engaged, along with a number of other countries, in the International Severe Acute Respiratory Infections Consortium.  This has established a global network of networks to monitor respiratory infections globally and could serve as a model for antimicrobial resistance monitoring.
default&#xa0;
default30.
default&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; 
defaultIn terms of coordinating research, the UK, represented through the MRC, has 
defaulton
default-
defaultgoing participation in the Joint
default Programming Initiative
default on Antimicrobial Resistance
default.  This aims 
defaultto streamline the European research efforts in 
defaultantimicrobial resistance
default by joint planning, implementation and evaluation of national research programmes.
default  This will lead to the launch of an interdisciplinary research agenda and other research councils will be invited to partner initiatives within their respective fields.
default&#xa0;
default31.
default&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; 
defaultThe UK has also worked with 
defaultCanadian Institute of Health Research
default (CIHR)
default 
defaultto set up research collaborations across the two countries directly focussed on antimicrobial resistance. Two consortia are currently funded
default by the MRC and 
defaultCIHR
default, totalling 
default£4m.
default&#xa0;
default32.
default&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; 
defaultBBSRC is a partner in the Global Strategic Alliance for the Coordination of Research on the Major Infectious Diseases of Animals and Zoonoses
default. The Alliance
default is considering 
defaultalternatives to antimicrobials and 
defaultantimicrobial resistance as a cross-cutting strategic theme
default.
default&#xa0;defaultWhat are the strengths and weaknesses of the Government’s 2013-2018 strategy for tackling antimicrobial resistance? What changes might be made to further strengthen the Government’s action plan?
default&#xa0;
default33.
default&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; 
defaultThe Government
default’s
default 
defaultstrategy 
defaulthas shown an inclusive approach and highlights a number of key areas for a range of stakeholders to engage with.  It provides a 
defaultglobal
default perspective and promotes interdisciplinary research, with a call to address some challenging areas of research. 
default&#xa0;
default34.
default&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; 
defaultWe recognise that the action plan is primarily focused on antibacterial resistance as this is the most significant problem for humans. The links with the 
defaultC
defaulthief 
defaultV
defaulteterinary 
defaultO
defaultfficer are strong and we welcome the recommendations made.  However, the strategy could have given more 
defaultemphasis to disease prevention strategies such as vaccination, especially in animals, as this would reduce antibiotic use.
default&#xa0;
default35.
default&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; 
defaultPotential weaknesses may include 
defaultlack of mention
default of knowledge exchange, especially as research
default encouraged by the strategy
default will be 
defaulthighly 
defaultinterdisciplinary.
default  Also, the implementation will need to be addressed.  
defaultPlans for this
default are discussed in the strategy however the research councils would welcome involvement 
defaultat all levels to 
defaulthelp 
defaultensure a joined up approach.
default&#xa0;
defaultNovember 2013
default&#xa0;
default 
defaultFurther details are available at 
defaultwww.rcuk.ac.uk
default 
default Cole, J (ed). 2013. Tackling Antimicrobial Resistance: Identifying Future Themes. STFC/RUSI Occasional Paper. 
default(
defaulthttp://www.rusi.org/publications/occasionalpapers/ref:O521C7E982D06B/
default)
default 
default Spoor LE, McAdam PR, Weinert LA, Rambaut A, Hasman H, Aarestrup FM, Kearns AM, Larsen AR, Skov RL, Fitzgerald JR. 2013. Livestock origin for a human pandemic clone of community-associated methicillin-resistant 
defaultStaphylococcus aureus
default. mBio 4(4):e00356-13. doi:10.1128/mBio.00356-13.
default 
defaulthttp://antibiotic-action.com/wp-content/uploads/2013/08/Learning-Lessons-report.pdf
default 
default £6.3m BBSRC, £4.8m MRC, £8.5m EPSRC
default